Mimedx (MDXG) Research & Development (2011 - 2026)

Mimedx has disclosed Research & Development across 16 years of filings, most recently posting $2.8 million for Q2 2026.

• In Q2 2026, Research & Development fell 15.92% year-over-year to $2.8 million; the TTM figure through Jun 2026 stood at $15.4 million (up 17.23% YoY), while the FY2025 annual figure was $15.1 million, up 22.33% from the prior year.
• Research & Development came in at $2.8 million for Q2 2026 at Mimedx, down from $4.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $6.0 million in Q1 2022 to a low of -$4.7 million in Q4 2022.
• Average Research & Development over 5 years is $3.3 million, with a median of $3.4 million recorded in 2023.
• Year-over-year, Research & Development sank 66.6% in 2022 and surged 151.46% in 2023.
• Over 5 years, Research & Development stood at -$4.7 million in 2022, then surged by 151.46% to $2.4 million in 2023, then soared by 46.77% to $3.6 million in 2024, then surged by 33.32% to $4.8 million in 2025, then sank by 41.67% to $2.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $2.8 million in Q2 2026, $4.1 million in Q1 2026, and $4.8 million in Q4 2025.